Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Medulloblastoma 3Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Carcinoma, Basal Cell 2Thrombocythemia, Essential 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Polycythemia Vera 1Pinealoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Neuroepithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Meningioma 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Imatinib Mesylate 18Dasatinib 12Cyclophosphamide 11fludarabine phosphate 9nilotinib 8fludarabine 7Sirolimus 6ruxolitinib 5Tacrolimus 5Mycophenolic Acid 5Cytarabine 5Azacitidine 5Whole-Body Irradiation 4Ipilimumab 4Busulfan 4Bortezomib 4thymoglobulin 3bosutinib 3belinostat 3aldesleukin 3Specimen Handling 3Nivolumab 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3CTLA-4 Antigen 3Antilymphocyte Serum 3AP 1903 reagent 3zileuton 2tozasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × sonidegib × Clear all
NCT01456676 2020-12-09

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Novartis

Phase 1 Completed
11 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡